Unknown

Lixian Zhong, PhD

Adjunct Assistant Professor of Pharmacy, Academic Institute
Houston Methodist


Biography

Dr. Zhong is an Assistant Professor of Rangel College of Pharmacy. Her research interest lies at the intersection of science, medicine and economics to assess clinical, economic and humanistic values of medical interventions and she conducts research on the costs and outcomes associated with pharmaceutical products.

She holds a Ph.D in Pharmacology and an M.A. in Economics from Duke University. She completed her post-doctoral fellowship training in Pharmacoeconomics and Outcomes research from University of California, San Francisco. She has conducted research in academic, international organization and industry settings.

Description of Research

Dr. Zhong has conducted research using clinical trial data, real world data, large survey data and economic modeling to study cost-effectiveness of new interventions for cancer and neurological diseases. Since joining Texas A&M University as an assistant professor at the College of Pharmacy in 2015, she is conducting research in: evaluating utilization, costs and outcomes associated with medications and other health care services in patients with chronic diseases, health disparity, cost-effectiveness of new interventions, drug pricing and reimbursement.

Publications

Dietary consumption trend and its correlation with global cancer burden: A quantitative and comprehensive analysis from 1990 to 2019
Luo, S, Lin, D, Lai, S, Lin, S, Zhong, L, Huang, X, Xu, X & Weng, X 2024, , Nutrition, vol. 117, 112225, pp. 112225. https://doi.org/10.1016/j.nut.2023.112225

Pharmacological Prescribing and Satisfaction with Pain Treatment Among Non-Hispanic Black Men with Chronic Pain
Oloruntoba, O, Bergeron, CD, Zhong, L, Merianos, AL, Sherman, LD, Kew, CL, Goidel, RK & Smith, ML 2024, , Patient Preference and Adherence, vol. 18, pp. 187-195. https://doi.org/10.2147/PPA.S435652

Examining Health Inequities in A1C Control over Time across Individual, Geospatial, and Geopolitical Factors among Adults with Type 2 Diabetes: Analyses of a Sample from One Commercial Insurer in a Southern State
Towne, SD, Ory, MG, Zhong, L, Smith, ML, Han, G, Andreyeva, E, Carpenter, K, Ahn, SN & Preston, VA 2024, , Journal of Primary Care and Community Health, vol. 15. https://doi.org/10.1177/21501319241253791

Group-based trajectory analysis identifies varying diabetes-related cost trajectories among type 2 diabetes patients in Texas: an empirical study using commercial insurance
Han, G, Spencer, MS, Ahn, SN, Smith, ML, Zhong, L, Andreyeva, E, Carpenter, K, Towne, SD, Preston, VA & Ory, MG 2023, , BMC Health Services Research, vol. 23, no. 1, 1116, pp. 1116. https://doi.org/10.1186/s12913-023-10118-1

Factors associated with higher hemoglobin A1c and type 2 diabetes-related costs: Secondary data analysis of adults 18 to 64 in Texas with commercial insurance
Ory, MG, Han, G, Jani, SN, Zhong, L, Andreyeva, E, Carpenter, K, Towne, SD, Preston, VA & Smith, ML 2023, , PLoS ONE, vol. 18, no. 9 September, e0289491. https://doi.org/10.1371/journal.pone.0289491

Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma–A Cost-Effectiveness Analysis
Lin, D, Luo, S, Lin, S, Zhong, L, Zhou, W, Gu, D, Huang, X, Chen, Q, Xu, X & Weng, X 2023, , Clinical Genitourinary Cancer, vol. 21, no. 1, pp. 8-15. https://doi.org/10.1016/j.clgc.2022.10.001

Disease burden of prostate cancer from 2014 to 2019 in the United States: estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey
Lin, S, Lin, D, Li, Y, Zhong, L, Zhou, W, Wu, Y, Xie, C, Luo, S, Huang, X, Xu, X & Weng, X 2023, , Epidemiology and health, vol. 45, pp. 1-8. https://doi.org/10.4178/epih.e2023038

External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations
Silva, P, Janjan, N, Ramos, K, Udeani, G, Zhong, L, Ory, MG & Smith, ML 2023, , Frontiers in Medicine, vol. 10, 1198088, pp. 1198088. https://doi.org/10.3389/fmed.2023.1198088

Factors Associated With In-Hospital Death Among Pneumonia Patients in US Hospitals From 2016~2019
Kim, SJ, Medina, M, Zhong, L & Chang, J 2023, , International Journal of Health Policy and Management, vol. 12, no. 1, 7390. https://doi.org/10.34172/ijhpm.2023.7390

Effectiveness of the Program to Encourage Active, Rewarding Lives (PEARLS) to reduce depression: a multi-state evaluation
Smith, ML, Steinman, LE, Montoya, CN, Thompson, M, Zhong, L & Merianos, AL 2023, , Frontiers in Public Health, vol. 11, 1169257, pp. 1169257. https://doi.org/10.3389/fpubh.2023.1169257

Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence
Weng, X, Zhong, L, Xiang, P, Li, Y, Paciorek, A, Dong, L, Broering, J, Carroll, PR, Sanda, M & Wilson, L 2022, , European Journal of Cancer Care, vol. 31, no. 6, e13740. https://doi.org/10.1111/ecc.13740

Physicians' interest in different strategies for supporting pain management and opioid prescribing: A cross-sectional study
Ory, MG, Lee, S, Dahlke, DV, Pardo, N, Zhong, L, McCord, CE, Alonzo, JP & Smith, ML 2022, , Journal of Opioid Management, vol. 18, no. 6, pp. 511-521. https://doi.org/10.5055/JOM.2022.0746

Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis
Berrios, K, Burum, A, Jeong, E & Zhong, L 2022, , Journal of Managed Care and Specialty Pharmacy, vol. 28, no. 11, pp. 1282-1291.

Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
Ionova, Y, Vuong, W, Sandoval, O, Fong, J, Vu, V, Zhong, L & Wilson, L 2022, , Clinical Drug Investigation, vol. 42, no. 6, pp. 491-500. https://doi.org/10.1007/s40261-022-01157-3

Real-World Data on Liposomal Bupivacaine and Inpatient Hospital Costs After Colorectal Surgery
Tran, AT, Rizk, E, Haas, EM, Naufal, G, Zhong, L & Swan, JT 2022, , Journal of Surgical Research, vol. 272, pp. 175-183. https://doi.org/10.1016/j.jss.2021.12.002

A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma
Chan, A, Dang, C, Wisniewski, J, Weng, X, Hynson, E, Zhong, L & Wilson, L 2022, , American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 45, no. 2, pp. 66-73. https://doi.org/10.1097/COC.0000000000000884

The economic burden of systemic sclerosis—A systematic review
Chen, Y, Wu, L, J. Hernández-Muñoz, J, J. Miller, M, Pope, M, Huyan, Y & Zhong, L 2022, , International Journal of Rheumatic Diseases, vol. 25, no. 2, pp. 110-120. https://doi.org/10.1111/1756-185X.14270

Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis
Dong, L, Lin, S, Zhong, L, Nian, D, Li, Y, Wang, R, Zhou, W, Weng, X & Xu, X 2022, , Clinical Breast Cancer, vol. 22, no. 1, pp. e21-e29. https://doi.org/10.1016/j.clbc.2021.06.001

Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
Narsipur, N, Bulla, S, Yoo, C, Do, B, Tran, K, Gu, D, Zhong, L & Wilson, L 2021, , Journal of Managed Care and Specialty Pharmacy, vol. 27, no. 12, pp. 1691-1702. https://doi.org/10.18553/JMCP.2021.27.12.1691

Effectiveness and economic impact of a diabetes education program among adults with type 2 diabetes in South Texas
Smith, ML, Zhong, L, Lee, S, Towne, SD & Ory, MG 2021, , BMC Public Health, vol. 21, no. 1, 1646, pp. 1646. https://doi.org/10.1186/s12889-021-11632-9

VIEW FULL PUBLICATIONS